ストックスクリーナーアプリを入手
5.08
9.48%
0.44
Aardvark Therapeutics Inc (AARD) 最新ニュース
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid - GlobeNewswire
AARD Technical Analysis & Stock Price Forecast - Intellectia AI
AARD Options Chain — NASDAQ:AARD - TradingView — Track All Markets
AARD Options Volatility — NASDAQ:AARD - TradingView — Track All Markets
Aardvark Therapeutics Halts HERO Trial, Shares Plunge 56% - Intellectia AI
Aardvark Therapeutics Shares Plunge After Trial Halt - Intellectia AI
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - Finviz
AARD Forecast, Price Target & Analyst Ratings | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman - GlobeNewswire Inc.
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Prader-Willi Syndrome Market Size in the 7MM was ~USD 600 million in 2023 and expected to grow by 2034, reveals DelveInsight - Barchart.com
[EFFECT] Aardvark Therapeutics, Inc. SEC Filing - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aardvark Therapeutics, Inc. (AARD) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aardvark Therapeutics, Inc. (AARD) And Encourages Shareholders to Reach Out | NDAQ:AARD | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Aardvark Therapeutics (AARD) price target decreased by 43.62% to 18.77 - MSN
Aardvark ups to $150M ATM sale with Piper Sandler (NASDAQ: AARD) - stocktitan.net
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Investors to Connect - ACCESS Newswire
Why Aardvark Therapeutics (AARD) paused late-stage ARD-101 trials after cardiac findings - msn.com
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings - Insider Monkey
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Significant Drop in Short Interest - MarketBeat
Why is Aardvark Therapeutics stock sinking Monday? - MSN
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
US Stocks Recap: Does Aardvark Therapeutics Inc align with a passive investing strategyWeekly Risk Report & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Heart activity changes prompted pause in trial of ARD-101 in PWS - Prader-Willi Syndrome News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - PR Newswire
Decliners Report: Can Aardvark Therapeutics Inc outperform under higher oil prices2026 Fed Impact & Long-Term Safe Investment Plans - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Stockholders to Connect - ACCESS Newswire
Aardvark Therapeutics, Inc. Files Form 8-K Announcing Entry Into Material Definitive Agreement – Company Details, Nasdaq Symbol AARD, and Contact Information - Minichart
Jones Trading cuts Aardvark Therapeutics stock price target on trial delay - Investing.com Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark ... - Bluefield Daily Telegraph
User - The Chronicle-Journal
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path By Investing.com - Investing.com Australia
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path - Investing.com
Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating By Investing.com - Investing.com India
AARD Stock Price and Chart — NASDAQ:AARD - TradingView
Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating - investing.com
B.Riley cuts Aardvark Therapeutics stock price target on trial pause By Investing.com - Investing.com South Africa
BTIG Research Reaffirms Buy Rating for Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Aardvark Therapeutics Inc. has officially signed an equity distribution agreement with Piper Sandler. - Bitget
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):